Talking points include:
About The Speaker:
Dr. Amel Karaa is a board certified internist and clinical geneticist, director of the mitochondrial disease program at the Massachusetts General Hospital in Boston. She received the 2013 United Mitochondrial Disease Foundation (UMDF) Fellowship and is conducting clinical research and clinical trials for mitochondrial disease. She was recently elected president of the Mitochondrial Medicine Society and sits on the scientific and medical board for MitoAction and the UMDF. Dr. Karaa is also on the board of Rare New England and the newly launched Mitochondrial Care Network. She is committed to being an advocate for her mitochondrial disease patients and their families and to educate adult providers in recognizing and treating mitochondrial patients within the community.
View slides on our website here.
Despite advances in newborn screening and treatment of fatty acid oxidation disorders, patients with very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD) continue to suffer from heart...
uy Miller, BioElectron’s CEO, and Matthew Klein, its Chief Medical Officer, will discuss the following: Challenges in the development of drugs for mitochondrial disease...
Dr. Bruce Cohen from the Cleveland Clinic in Ohio discusses his perspective on the use of hyperbaric oxygen therapy, also known as HBOT, for...